Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H25ClN2O9 |
| Molecular Weight | 508.906 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(O)C=CC(Cl)=C4[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(=O)NCO)=C1O
InChI
InChIKey=GJGDLRSSCNAKGL-KMVLDZISSA-N
InChI=1S/C23H25ClN2O9/c1-22(34)8-6-9-16(26(2)3)18(30)14(21(33)25-7-27)20(32)23(9,35)19(31)12(8)17(29)13-11(28)5-4-10(24)15(13)22/h4-5,8-9,16,27-28,30-31,34-35H,6-7H2,1-3H3,(H,25,33)/t8-,9-,16-,22-,23-/m0/s1
| Molecular Formula | C23H25ClN2O9 |
| Molecular Weight | 508.906 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Clomocycline is the approved name of a methylol derivative of chlortetracycline. Clomocycline is a tetracycline antibiotic that is commonly prescribed by medical doctors for infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Clomocycline is also used commonly as a prophylactic treatment for infection by Bacillus anthracis (anthrax). It is also effective against Yersinia pestis and malaria and is also prescribed for the treatment of Lyme disease. Clomocycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Clomocycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. This drug has been reported to be noticeably free of side-effects such as nausea, vomiting, and diarrhea.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4892122
17 mg/kg (1 capsule per 10 kg.) in a single dose or two doses taken at an interval of 6-8 hours;
34 mg/kg divided into two or three doses taken at 6-hourly intervals
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:57 GMT 2025
by
admin
on
Mon Mar 31 18:21:57 GMT 2025
|
| Record UNII |
YP0241BU76
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J01AA11
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
||
|
NCI_THESAURUS |
C1595
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
||
|
WHO-VATC |
QJ01AA11
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID80905089
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
100000084527
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
59589
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
CLOMOCYCLINE
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
C007090
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
2151
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
1181-54-0
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106071
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
YP0241BU76
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
SUB06726MIG
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
m1081
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB00453
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
702
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | |||
|
21272
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY | RxNorm | ||
|
C76236
Created by
admin on Mon Mar 31 18:21:57 GMT 2025 , Edited by admin on Mon Mar 31 18:21:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |